Yang-xin Fu

List of Publications by Year in Descending Order

319 papers	28,493 citations	85 h-index	162 g-index
342 ext. papers	34,164 ext. citations	14.3 avg, IF	7.18 L-index

#	Paper	IF	Citations
319	Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity.. *Journal of Clinical Investigation*, **2022**, 132,	15.9	4
318	A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors.. *Science Immunology*, **2022**, 7, eabi6899	28	2
317	Sequential immunization with SARS-CoV-2 RBD vaccine induces potent and broad neutralization against variants in mice.. *Virology Journal*, **2022**, 19, 2	6.1	1
316	A single factor elicits multilineage reprogramming of astrocytes in the adult mouse striatum.. *Proceedings of the National Academy of Sciences of the United States of America*, **2022**, 119, e2107339119	11.5	0
315	AXL targeting restores PD-1 blockade sensitivity of mutant NSCLC through expansion of TCF1 CD8 T□cells.. *Cell Reports Medicine*, **2022**, 3, 100554	18	4
314	Concurrent delivery of immune checkpoint blockade modulates T cell dynamics to enhance neoantigen vaccine-generated antitumor immunity.. *Nature Cancer*, **2022**,	15.4	5
313	Non-adjuvanted interferon-armed RBD protein nasal drops protect airway infection from SARS-CoV-2.. *Cell Discovery*, **2022**, 8, 43	22.3	0
312	ZMYND8 Expression in Breast Cancer Cells Blocks T-Lymphocyte Surveillance to Promote Tumor Growth. *Cancer Research*, **2021**, 81, 174-186	10.1	5
311	Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma. *Clinical Cancer Research*, **2021**,	12.9	2
310	602 AXL targeting with bemcentinb restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through innate immune cell mediated expansion of TCF1+ CD8 T cells **2021**, 9, A632-A632		
309	Broad neutralization against SARS-CoV-2 variants induced by a next-generation protein vaccine V-01. *Cell Discovery*, **2021**, 7, 114	22.3	2
308	All-trans retinoic acid overcomes solid tumor radioresistance by inducing inflammatory macrophages. *Science Immunology*, **2021**, 6,	28	2
307	Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance. *Nature Communications*, **2021**, 12, 5866	17.4	6
306	Rejuvenation of tumour-specific T cells through bispecific antibodies targeting PD-L1 on dendritic cells. *Nature Biomedical Engineering*, **2021**, 5, 1261-1273	19	8
305	Type I IFN Activating Type I Dendritic Cells for Antitumor Immunity. *Clinical Cancer Research*, **2021**, 27, 3818-3824	12.9	1
304	Next-generation cytokines for cancer immunotherapy. *Antibody Therapeutics*, **2021**, 4, 123-133	5.8	5
303	A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy. *Nature Communications*, **2021**, 12, 2768	17.4	8

302	The AIM2 and NLRP3 inflammasomes trigger IL-1-mediated antitumor effects during radiation. *Science Immunology*, **2021**, 6,	28	4
301	Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8 T cell immunity. *Cell Metabolism*, **2021**, 33, 988-1000.e7	24.6	49
300	Small molecular drugs reshape tumor microenvironment to synergize with immunotherapy. *Oncogene*, **2021**, 40, 885-898	9.2	5
299	MLH1 Deficiency-Triggered DNA Hyperexcision by Exonuclease 1 Activates the cGAS-STING Pathway. *Cancer Cell*, **2021**, 39, 109-121.e5	24.3	42
298	DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity. *Cancer Cell*, **2021**, 39, 96-108.e6	24.3	42
297	A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity. *Science Translational Medicine*, **2021**, 13,	17.5	13
296	Tissue-resident CD4 T helper cells assist the development of protective respiratory B and CD8 T cell memory responses. *Science Immunology*, **2021**, 6,	28	42
295	Suppression of local type I interferon by gut microbiota-derived butyrate impairs antitumor effects of ionizing radiation. *Journal of Experimental Medicine*, **2021**, 218,	16.6	12
294	Prolonged activation of innate immune pathways by a polyvalent STING agonist. *Nature Biomedical Engineering*, **2021**, 5, 455-466	19	49
293	Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity. *Science Translational Medicine*, **2021**, 13,	17.5	12
292	Proteolysis-targeting chimera against BCL-X destroys tumor-infiltrating regulatory T cells. *Nature Communications*, **2021**, 12, 1281	17.4	13
291	Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts. *Cell Reports*, **2021**, 36, 109422	10.6	16
290	Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2. *Cell Research*, **2021**, 31, 1011-1023	24.7	18
289	Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity. *Cell Research*, **2021**, 31, 1190-1198	24.7	5
288	Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Preclinical Models Enhances Single-Agent Immune Checkpoint Blockade. *International Journal of Radiation Oncology Biology Physics*, **2021**, 110, 1306-1316	4	7
287	Dual targeting of CTLA-4 and CD47 on T cells promotes immunity against solid tumors. *Science Translational Medicine*, **2021**, 13,	17.5	8
286	Type I Interferon Response in Radiation-Induced Anti-Tumor Immunity. *Seminars in Radiation Oncology*, **2020**, 30, 129-138	5.5	7
285	Cytokines that target immune killer cells against tumors. *Cellular and Molecular Immunology*, **2020**, 17, 722-727	15.4	7

284	Tumor cells suppress radiation-induced immunity by hijacking caspase 9 signaling. *Nature Immunology*, **2020**, 21, 546-554	19.1	36
283	Chemotherapy Induces Cancer-Fighting B Cells. *Cell*, **2020**, 180, 1037-1039	56.2	9
282	Telomere Stress Potentiates STING-Dependent Anti-tumor Immunity. *Cancer Cell*, **2020**, 38, 400-411.e6	24.3	15
281	Gliomas Interact with Non-glioma Brain Cells via Extracellular Vesicles. *Cell Reports*, **2020**, 30, 2489-2500.e56	10.6	30
280	Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B. *Nature Nanotechnology*, **2020**, 15, 406-416	28.7	71
279	eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer. *Nature Cancer*, **2020**, 1, 533-545	15.4	35
278	Differential regulation of breast cancer bone metastasis by PARP1 and PARP2. *Nature Communications*, **2020**, 11, 1578	17.4	11
277	Targeting tumors with IL-21 reshapes the tumor microenvironment by proliferating PD-1intTim-3-CD8+ T cells. *JCI Insight*, **2020**, 5,	9.9	12
276	A PoleP286R mouse model of endometrial cancer recapitulates high mutational burden and immunotherapy response. *JCI Insight*, **2020**, 5,	9.9	10
275	Hybrid cellular membrane nanovesicles amplify macrophage immune responses against cancer recurrence and metastasis. *Nature Communications*, **2020**, 11, 4909	17.4	80
274	Targeting innate sensing in the tumor microenvironment to improve immunotherapy. *Cellular and Molecular Immunology*, **2020**, 17, 13-26	15.4	35
273	Investigation of Antigen-Specific T-Cell Receptor Clusters in Human Cancers. *Clinical Cancer Research*, **2020**, 26, 1359-1371	12.9	42
272	RIG-I-Like Receptor LGP2 Is Required for Tumor Control by Radiotherapy. *Cancer Research*, **2020**, 80, 5633-5641	10.1	9
271	The Interaction between Lymphoid Tissue Inducer-Like Cells and T Cells in the Mesenteric Lymph Node Restrains Intestinal Humoral Immunity. *Cell Reports*, **2020**, 32, 107936	10.6	7
270	Targeting the myeloid checkpoint receptor SIRP potentiates innate and adaptive immune responses to promote anti-tumor activity. *Journal of Hematology and Oncology*, **2020**, 13, 160	22.4	11
269	Catenin regulates tumor-derived PD-L1. *Journal of Experimental Medicine*, **2020**, 217,	16.6	5
268	Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling. *Journal of Experimental Medicine*, **2020**, 217,	16.6	70
267	PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. *Nature Communications*, **2020**, 11, 4835	17.4	94

266	CD160 Plays a Protective Role During Chronic Infection by Enhancing Both Functionalities and Proliferative Capacity of CD8+ T Cells. *Frontiers in Immunology*, **2020**, 11, 2188	8.4	4
265	De novo prediction of cancer-associated T cell receptors for noninvasive cancer detection. *Science Translational Medicine*, **2020**, 12,	17.5	20
264	A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8 T-cell response and effective tumor control. *Nature Communications*, **2019**, 10, 3874	17.4	71
263	Phagocytosis checkpoints as new targets for cancer immunotherapy. *Nature Reviews Cancer*, **2019**, 19, 568-586	31.3	240
262	Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma **2019**, 7, 79		15
261	Tumor-reprogrammed resident T cells resist radiation to control tumors. *Nature Communications*, **2019**, 10, 3959	17.4	85
260	Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8 T Cell Apoptosis. *Cancer Cell*, **2019**, 35, 901-915.e4	24.3	45
259	A bioactive mammalian disaccharide associated with autoimmunity activates STING-TBK1-dependent immune response. *Nature Communications*, **2019**, 10, 2377	17.4	9
258	LKB1 orchestrates dendritic cell metabolic quiescence and anti-tumor immunity. *Cell Research*, **2019**, 29, 391-405	24.7	24
257	Synergistic STING activation by PC7A nanovaccine and ionizing radiation improves cancer immunotherapy. *Journal of Controlled Release*, **2019**, 300, 154-160	11.7	38
256	The Aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy. *Nature Communications*, **2019**, 10, 1125	17.4	73
255	Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity. *Science Immunology*, **2019**, 4,	28	16
254	NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance. *Nature Communications*, **2019**, 10, 3251	17.4	26
253	CD160 serves as a negative regulator of NKT cells in acute hepatic injury. *Nature Communications*, **2019**, 10, 3258	17.4	12
252	Degradation of CTLA-4 balances toxicity and efficacy. *Science Bulletin*, **2019**, 64, 1388-1389	10.6	1
251	Exploits CD209 Receptors for Promoting Host Dissemination and Infection. *Infection and Immunity*, **2019**, 87,	3.7	13
250	A Critical Role of the IL-1β–IL-1R Signaling Pathway in Skin Inflammation and Psoriasis Pathogenesis. *Journal of Investigative Dermatology*, **2019**, 139, 146-156	4.3	62
249	Immune Evasion in Tumor's Own Sweet Way. *Cell Metabolism*, **2018**, 27, 945-946	24.6	7

248	A PI3K p110δ-selective inhibitor enhances the efficacy of anti-HER2/neu antibody therapy against breast cancer in mice. *OncoImmunology*, **2018**, 7, e1421890	7.2	5
247	Low-dose X-ray radiotherapy-radiodynamic therapy via nanoscale metal-organic frameworks enhances checkpoint blockade immunotherapy. *Nature Biomedical Engineering*, **2018**, 2, 600-610	19	292
246	Lymphotoxin in physiology of lymphoid tissues - Implication for antiviral defense. *Cytokine*, **2018**, 101, 39-47	4	9
245	Macrophage-derived IL-1β promotes sterile inflammation in a mouse model of acetaminophen hepatotoxicity. *Cellular and Molecular Immunology*, **2018**, 15, 973-982	15.4	52
244	T Cell-Derived Lymphotoxin Is Essential for the Anti-Herpes Simplex Virus 1 Humoral Immune Response. *Journal of Virology*, **2018**, 92,	6.6	3
243	Dual Targeting of Innate and Adaptive Checkpoints on Tumor Cells Limits Immune Evasion. *Cell Reports*, **2018**, 24, 2101-2111	10.6	55
242	Targeting Tertiary Lymphoid Structures for Tumor Immunotherapy. *Methods in Molecular Biology*, **2018**, 1845, 275-286	1.4	7
241	Non-canonical NF-κB Antagonizes STING Sensor-Mediated DNA Sensing in Radiotherapy. *Immunity*, **2018**, 49, 490-503.e4	32.3	77
240	Polymerase-mediated ultramutagenesis in mice produces diverse cancers with high mutational load. *Journal of Clinical Investigation*, **2018**, 128, 4179-4191	15.9	36
239	Type 3 innate lymphoid cell-derived lymphotoxin prevents microbiota-dependent inflammation. *Cellular and Molecular Immunology*, **2018**, 15, 697-709	15.4	8
238	Another way to not get eaten. *Nature Immunology*, **2018**, 19, 6-7	19.1	5
237	T cell-derived lymphotoxin limits Th1 response during HSV-1 infection. *Scientific Reports*, **2018**, 8, 17727	4.9	0
236	Targeting tumor cells with antibodies enhances anti-tumor immunity. *Biophysics Reports*, **2018**, 4, 243-253	3.5	11
235	Targeting IFNβ to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance. *Nature Communications*, **2018**, 9, 4586	17.4	30
234	LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. *Nature*, **2018**, 562, 605-609	50.4	81
233	PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. *Journal of Clinical Investigation*, **2018**, 128, 580-588	15.9	259
232	CTLA-4 Limits Anti-CD20-Mediated Tumor Regression. *Clinical Cancer Research*, **2017**, 23, 193-203	12.9	25
231	Is CD47 an innate immune checkpoint for tumor evasion?. *Journal of Hematology and Oncology*, **2017**, 10, 12	22.4	101

230	DNA sensing and immune responses in cancer therapy. *Current Opinion in Immunology*, **2017**, 45, 16-20	7.8	13
229	Radiotherapy and immunotherapy: a beneficial liaison?. *Nature Reviews Clinical Oncology*, **2017**, 14, 365-379	19.4	504
228	LIGHT Elevation Enhances Immune Eradication of Colon Cancer Metastases. *Cancer Research*, **2017**, 77, 1880-1891	10.1	28
227	Coordinating antigen cytosolic delivery and danger signaling to program potent cross-priming by micelle-based nanovaccine. *Cell Discovery*, **2017**, 3, 17007	22.3	30
226	A STING-activating nanovaccine for cancer immunotherapy. *Nature Nanotechnology*, **2017**, 12, 648-654	28.7	441
225	Lymphotoxin signalling in tertiary lymphoid structures and immunotherapy. *Cellular and Molecular Immunology*, **2017**, 14, 809-818	15.4	24
224	Bap180/Baf180 is required to maintain homeostasis of intestinal innate immune response in Drosophila and mice. *Nature Microbiology*, **2017**, 2, 17056	26.6	22
223	Tbet and IL-36R cooperate in therapeutic DC-mediated promotion of ectopic lymphoid organogenesis in the tumor microenvironment. *OncoImmunology*, **2017**, 6, e1322238	7.2	37
222	Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice. *Hepatology*, **2017**, 66, 1067-1082	11.2	33
221	Cutting Edge: Lymphotoxin Signaling Is Essential for Clearance of Salmonella from the Gut Lumen and Generation of Anti-Salmonella Protective Immunity. *Journal of Immunology*, **2017**, 198, 55-60	5.3	5
220	Converting Lymphoma Cells into Potent Antigen-Presenting Cells for Interferon-Induced Tumor Regression. *Cancer Immunology Research*, **2017**, 5, 560-570	12.5	7
219	IL-22 Upregulates Epithelial Claudin-2 to Drive Diarrhea and Enteric Pathogen Clearance. *Cell Host and Microbe*, **2017**, 21, 671-681.e4	23.4	104
218	Dendritic Cells but Not Macrophages Sense Tumor Mitochondrial DNA for Cross-priming through Signal Regulatory Protein Signaling. *Immunity*, **2017**, 47, 363-373.e5	32.3	126
217	Host STING-dependent MDSC mobilization drives extrinsic radiation resistance. *Nature Communications*, **2017**, 8, 1736	17.4	193
216	From DNA Damage to Nucleic Acid Sensing: A Strategy to Enhance Radiation Therapy. *Clinical Cancer Research*, **2016**, 22, 20-5	12.9	53
215	Opposite Effects of Coinjection and Distant Injection of Mesenchymal Stem Cells on Breast Tumor Cell Growth. *Stem Cells Translational Medicine*, **2016**, 5, 1216-28	6.9	16
214	The intersection of radiotherapy and immunotherapy: mechanisms and clinical implications. *Science Immunology*, **2016**, 1,	28	101
213	LTR controls thymic portal endothelial cells for haematopoietic progenitor cell homing and T-cell regeneration. *Nature Communications*, **2016**, 7, 12369	17.4	18

212	Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse. *Science Translational Medicine*, **2016**, 8, 333ra47	17.5	60
211	PD-1 Shapes B Cells as Evildoers in the Tumor Microenvironment. *Cancer Discovery*, **2016**, 6, 477-8	24.4	26
210	Purification and Adoptive Transfer of Group 3 Gut Innate Lymphoid Cells. *Methods in Molecular Biology*, **2016**, 1422, 189-96	1.4	10
209	A novel dendritic cell targeting HPV16 E7 synthetic vaccine in combination with PD-L1 blockade elicits therapeutic antitumor immunity in mice. *OncoImmunology*, **2016**, 5, e1147641	7.2	30
208	Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade. *Cancer Cell*, **2016**, 29, 285-296	24.3	227
207	Adapting conventional cancer treatment for immunotherapy. *Journal of Molecular Medicine*, **2016**, 94, 489-95	5.5	25
206	Clearing Persistent Extracellular Antigen of Hepatitis B Virus: An Immunomodulatory Strategy To Reverse Tolerance for an Effective Therapeutic Vaccination. *Journal of Immunology*, **2016**, 196, 3079-87	5.3	50
205	The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies. *Trends in Immunology*, **2016**, 37, 141-153	14.4	19
204	Immunotherapy and tumor microenvironment. *Cancer Letters*, **2016**, 370, 85-90	9.9	164
203	Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance. *Oncotarget*, **2016**, 7, 43039-43051	3.3	51
202	The ETS1 transcription factor is required for the development and cytokine-induced expansion of ILC2. *Journal of Experimental Medicine*, **2016**, 213, 687-96	16.6	56
201	Radiotherapy and immune checkpoint blockade: potential interactions and future directions. *Trends in Molecular Medicine*, **2015**, 21, 463-5	11.5	22
200	Intratumoral Delivery of IL-21 Overcomes Anti-Her2/Neu Resistance through Shifting Tumor-Associated Macrophages from M2 to M1 Phenotype. *Journal of Immunology*, **2015**, 194, 4997-5006	5.3	77
199	Innate Lymphoid Cells Control Early Colonization Resistance against Intestinal Pathogens through ID2-Dependent Regulation of the Microbiota. *Immunity*, **2015**, 42, 731-43	32.3	73
198	A dendritic-cell-stromal axis maintains immune responses in lymph nodes. *Immunity*, **2015**, 42, 719-30	32.3	53
197	Effector lymphocyte-induced lymph node-like vasculature enables naive T-cell entry into tumours and enhanced anti-tumour immunity. *Nature Communications*, **2015**, 6, 7114	17.4	95
196	Addition of anti-neu antibody to local irradiation can improve tumor-bearing BALB/c mouse survival through immune-mediated mechanisms. *Radiation Research*, **2015**, 183, 271-8	3.1	4
195	CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. *Nature Medicine*, **2015**, 21, 1209-15	50.5	405

194	GITR subverts Foxp3(+) Tregs to boost Th9 immunity through regulation of histone acetylation. *Nature Communications*, **2015**, 6, 8266	17.4	75
193	Innate lymphotoxin receptor mediated signaling promotes HSV-1 associated neuroinflammation and viral replication. *Scientific Reports*, **2015**, 5, 10406	4.9	5
192	CD160 is essential for NK-mediated IFN- production. *Journal of Experimental Medicine*, **2015**, 212, 415-29	16.6	65
191	Deficiency of CD40 Reveals an Important Role for LIGHT in Anti-Leishmania Immunity. *Journal of Immunology*, **2015**, 195, 194-202	5.3	9
190	Interferon-induced mechanosensing defects impede apoptotic cell clearance in lupus. *Journal of Clinical Investigation*, **2015**, 125, 2877-90	15.9	38
189	The tragic fate of group 3 innate lymphoid cells during HIV-1 infection. *Journal of Clinical Investigation*, **2015**, 125, 3430-2	15.9	4
188	A BTLA-mediated bait and switch strategy permits Listeria expansion in CD8(+) DCs to promote long-term T cell responses. *Cell Host and Microbe*, **2014**, 16, 68-80	23.4	9
187	Commensal bacteria protect against food allergen sensitization. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 13145-50	11.5	476
186	Targeting the tumor microenvironment with interferon- bridges innate and adaptive immune responses. *Cancer Cell*, **2014**, 25, 37-48	24.3	186
185	Induction of innate lymphoid cell-derived interleukin-22 by the transcription factor STAT3 mediates protection against intestinal infection. *Immunity*, **2014**, 40, 25-39	32.3	159
184	Lymphotoxin organizes contributions to host defense and metabolic illness from innate lymphoid cells. *Cytokine and Growth Factor Reviews*, **2014**, 25, 227-33	17.9	10
183	Innate lymphoid cells facilitate NK cell development through a lymphotoxin-mediated stromal microenvironment. *Journal of Experimental Medicine*, **2014**, 211, 1421-31	16.6	13
182	Targeting CD137 enhances the efficacy of cetuximab. *Journal of Clinical Investigation*, **2014**, 124, 2668-82	15.9	137
181	A novel method for synthetic vaccine construction based on protein assembly. *Scientific Reports*, **2014**, 4, 7266	4.9	55
180	Anti-HER2/Neu passive-aggressive immunotherapy. *OncoImmunology*, **2014**, 3, e27296	7.2	3
179	Hepatitis B virus infection and immunopathogenesis in a humanized mouse model: induction of human-specific liver fibrosis and M2-like macrophages. *PLoS Pathogens*, **2014**, 10, e1004032	7.6	147
178	A mouse model for HBV immunotolerance and immunotherapy. *Cellular and Molecular Immunology*, **2014**, 11, 71-8	15.4	77
177	Therapeutic activity of high-dose intratumoral IFN- requires direct effect on the tumor vasculature. *Journal of Immunology*, **2014**, 193, 4254-60	5.3	58

176	STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. *Immunity*, **2014**, 41, 843-52	32.3	985
175	Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression. *OncoImmunology*, **2014**, 3, e28499	7.2	51
174	Intratumoral heterogeneity impacts the response to anti-neu antibody therapy. *BMC Cancer*, **2014**, 14, 647	4.8	14
173	Pathological functions of interleukin-22 in chronic liver inflammation and fibrosis with hepatitis B virus infection by promoting T helper 17 cell recruitment. *Hepatology*, **2014**, 59, 1331-42	11.2	124
172	Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. *Journal of Clinical Investigation*, **2014**, 124, 687-95	15.9	1191
171	Tolerogenic properties of lymphatic endothelial cells are controlled by the lymph node microenvironment. *PLoS ONE*, **2014**, 9, e87740	3.7	61
170	Adaptive Immune Responses and HER2/neu Positive Breast Cancer. *Current Pathobiology Reports*, **2013**, 1, 37-42	2	9
169	Group 3 innate lymphoid cells inhibit T-cell-mediated intestinal inflammation through aryl hydrocarbon receptor signaling and regulation of microflora. *Immunity*, **2013**, 39, 386-99	32.3	292
168	Innate and adaptive immune cells in the tumor microenvironment. *Nature Immunology*, **2013**, 14, 1014-22	29.1	2160
167	Cetuximab-mediated tumor regression depends on innate and adaptive immune responses. *Molecular Therapy*, **2013**, 21, 91-100	11.7	84
166	OTUD7B controls non-canonical NF-B activation through deubiquitination of TRAF3. *Nature*, **2013**, 494, 371-4	50.4	148
165	Type I interferon response and innate immune sensing of cancer. *Trends in Immunology*, **2013**, 34, 67-73	14.4	190
164	Lymphotoxin signalling in immune homeostasis and the control of microorganisms. *Nature Reviews Immunology*, **2013**, 13, 270-9	36.5	68
163	The role of tumor-associated macrophages in breast cancer progression (review). *International Journal of Oncology*, **2013**, 43, 5-12	4.4	139
162	TNFR2 activates MLCK-dependent tight junction dysregulation to cause apoptosis-mediated barrier loss and experimental colitis. *Gastroenterology*, **2013**, 145, 407-15	13.3	228
161	Radiation-induced tumor dormancy reflects an equilibrium between the proliferation and T lymphocyte-mediated death of malignant cells. *OncoImmunology*, **2013**, 2, e25668	7.2	11
160	Linking the microbiota and metabolic disease with lymphotoxin. *International Immunology*, **2013**, 25, 397-403	4.9	4
159	Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell-mediated killing. *Journal of Immunology*, **2013**, 190, 5874-81	5.3	122

158	Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer. *Cancer Immunology Research*, **2013**, 1, 123-33	12.5	52
157	Effective anti-neu-initiated antitumor responses require the complex role of CD4+ T cells. *Clinical Cancer Research*, **2013**, 19, 1476-86	12.9	43
156	LIGHT/TNFSR14 can regulate hepatic lipase expression by hepatocytes independent of T cells and Kupffer cells. *PLoS ONE*, **2013**, 8, e54719	3.7	9
155	Radiation-inducible immunotherapy for cancer: senescent tumor cells as a cancer vaccine. *Molecular Therapy*, **2012**, 20, 1046-55	11.7	53
154	Lymphotoxin regulates commensal responses to enable diet-induced obesity. *Nature Immunology*, **2012**, 13, 947-53	19.1	103
153	B cell maintenance of subcapsular sinus macrophages protects against a fatal viral infection independent of adaptive immunity. *Immunity*, **2012**, 36, 415-26	32.3	109
152	OX40 signaling favors the induction of T(H)9 cells and airway inflammation. *Nature Immunology*, **2012**, 13, 981-90	19.1	163
151	The aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells. *Immunity*, **2012**, 36, 92-104	32.3	545
150	The tumor immunosuppressive microenvironment impairs the therapy of anti-HER2/neu antibody. *Protein and Cell*, **2012**, 3, 441-9	7.2	5
149	LIGHT delivery to tumors by mesenchymal stem cells mobilizes an effective antitumor immune response. *Cancer Research*, **2012**, 72, 2980-9	10.1	34
148	Targeting and utilizing primary tumors as live vaccines: changing strategies. *Cellular and Molecular Immunology*, **2012**, 9, 20-6	15.4	5
147	The confluence of radiotherapy and immunotherapy. *Frontiers in Oncology*, **2012**, 2, 143	5.3	46
146	Lymphotoxin controls the IL-22 protection pathway in gut innate lymphoid cells during mucosal pathogen challenge. *Cell Host and Microbe*, **2011**, 10, 44-53	23.4	165
145	Attenuation by targeting the B- and T-cell attenuator. *Transplantation*, **2011**, 92, 1075-6	1.8	1
144	The role of core TNF/LIGHT family members in lymph node homeostasis and remodeling. *Immunological Reviews*, **2011**, 244, 75-84	11.3	39
143	Deflating the lymph node. *Immunity*, **2011**, 34, 8-10	32.3	2
142	Active immunotherapy combined with blockade of a coinhibitory pathway achieves regression of large tumor masses in cancer-prone mice. *Molecular Therapy*, **2011**, 19, 1727-36	11.7	34
141	Growth-factor receptor-bound protein-2 (Grb2) signaling in B cells controls lymphoid follicle organization and germinal center reaction. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 7926-31	11.5	36

140	LIGHT regulates inflamed draining lymph node hypertrophy. *Journal of Immunology*, **2011**, 186, 7156-63	5.3	27
139	B and T lymphocyte attenuator down-regulation by HIV-1 depends on type I interferon and contributes to T-cell hyperactivation. *Journal of Infectious Diseases*, **2011**, 203, 1668-78	7	25
138	The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. *Cancer Research*, **2011**, 71, 2488-96	10.1	549
137	CD95 promotes tumour growth. *Nature*, **2010**, 465, 492-6	50.4	286
136	LIGHT induces distinct signals to clear an AAV-expressed persistent antigen in the mouse liver and to induce liver inflammation. *PLoS ONE*, **2010**, 5, e10585	3.7	3
135	Promoting immune responses by LIGHT in the face of abundant regulatory T cell inhibition. *Journal of Immunology*, **2010**, 184, 1589-95	5.3	16
134	Antigen persistence and the control of local T cell memory by migrant respiratory dendritic cells after acute virus infection. *Journal of Experimental Medicine*, **2010**, 207, 1161-72	16.6	122
133	Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. *Journal of Experimental Medicine*, **2010**, 207, 1791-804	16.6	174
132	Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regression. *Cancer Research*, **2010**, 70, 3955-64	10.1	27
131	Direct and indirect roles of the LTbetaR pathway in central tolerance induction. *Trends in Immunology*, **2010**, 31, 325-31	14.4	15
130	Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. *Seminars in Oncology*, **2010**, 37, 508-16	5.5	220
129	The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. *Cancer Cell*, **2010**, 18, 160-70	24.3	372
128	IgE regulates T helper cell differentiation through FcgammaRIII mediated dendritic cell cytokine modulation. *Cellular Immunology*, **2010**, 264, 54-60	4.4	15
127	Lymphotoxin beta receptor signaling in intestinal epithelial cells orchestrates innate immune responses against mucosal bacterial infection. *Immunity*, **2010**, 32, 403-13	32.3	122
126	The Prognostic Significance of Tumor-Infiltrating Lymphocytes **2010**, 385-407		
125	Targeting lymphotoxin-mediated negative selection to prevent prostate cancer in mice with genetic predisposition. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 17134-9	11.5	15
124	B and T lymphocyte attenuator tempers early infection immunity. *Journal of Immunology*, **2009**, 183, 1946-51	5.3	45
123	Cutting edge: B and T lymphocyte attenuator signaling on NKT cells inhibits cytokine release and tissue injury in early immune responses. *Journal of Immunology*, **2009**, 183, 32-6	5.3	41

122	Lymphotoxin beta receptor signaling promotes tertiary lymphoid organogenesis in the aorta adventitia of aged ApoE-/- mice. *Journal of Experimental Medicine*, **2009**, 206, 233-48	16.6	269
121	The Role of NF-B in Central Tolerance **2009**, 39-54		
120	Immunoregulation by tumor necrosis factor superfamily member LIGHT. *Immunological Reviews*, **2009**, 229, 232-43	11.3	30
119	Do adaptive immune cells suppress or activate innate immunity?. *Trends in Immunology*, **2009**, 30, 8-12	14.4	22
118	T cell-derived lymphotoxin regulates liver regeneration. *Gastroenterology*, **2009**, 136, 694-704.e4	13.3	54
117	Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. *Blood*, **2009**, 114, 589-95	2.2	925
116	Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B. *Gastroenterology*, **2008**, 134, 1938-49, 1949.e1-3	13.3	120
115	Coordinating development of medullary thymic epithelial cells. *Immunity*, **2008**, 29, 386-8	32.3	16
114	Targeting tumors with LIGHT to generate metastasis-clearing immunity. *Cytokine and Growth Factor Reviews*, **2008**, 19, 285-94	17.9	46
113	Equilibrium between host and cancer caused by effector T cells killing tumor stroma. *Cancer Research*, **2008**, 68, 1563-71	10.1	67
112	Phospholipase Cgamma2 mediates RANKL-stimulated lymph node organogenesis and osteoclastogenesis. *Journal of Biological Chemistry*, **2008**, 283, 29593-601	5.4	20
111	Hyper innate responses in neonates lead to increased morbidity and mortality after infection. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 7528-33	11.5	129
110	The inhibitory HVEM-BTLA pathway counter regulates lymphotoxin receptor signaling to achieve homeostasis of dendritic cells. *Journal of Immunology*, **2008**, 180, 238-48	5.3	76
109	Gadd45beta promotes hepatocyte survival during liver regeneration in mice by modulating JNK signaling. *Journal of Clinical Investigation*, **2008**, 118, 1911-23	15.9	70
108	Lymphotoxin beta receptor is required for the migration and selection of autoreactive T cells in thymic medulla. *FASEB Journal*, **2008**, 22, 669.13	0.9	
107	Hypersensitivity of innate response to TLRs in neonate. *FASEB Journal*, **2008**, 22, 672.9	0.9	
106	LIGHT signals directly to intestinal epithelia to cause barrier dysfunction via cytoskeletal and endocytic mechanisms. *Gastroenterology*, **2007**, 132, 2383-94	13.3	140
105	Intratumor Generation of Vigorous Antitumor Immune Responses **2007**, 229-242		

104	B and T lymphocyte attenuator regulates CD8+ T cell-intrinsic homeostasis and memory cell generation. *Nature Immunology*, **2007**, 8, 162-71	19.1	110
103	Adaptive immune cells temper initial innate responses. *Nature Medicine*, **2007**, 13, 1248-52	50.5	272
102	Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. *Journal of Immunology*, **2007**, 179, 1960-8	5.3	66
101	LIGHT Is critical for IL-12 production by dendritic cells, optimal CD4+ Th1 cell response, and resistance to Leishmania major. *Journal of Immunology*, **2007**, 179, 6901-9	5.3	44
100	Lymphotoxin beta receptor is required for the migration and selection of autoreactive T cells in thymic medulla. *Journal of Immunology*, **2007**, 179, 8069-75	5.3	55
99	Lymphotoxin beta receptor (Lt betaR): dual roles in demyelination and remyelination and successful therapeutic intervention using Lt betaR-Ig protein. *Journal of Neuroscience*, **2007**, 27, 7429-37	6.6	41
98	Lymphotoxin beta receptor-dependent control of lipid homeostasis. *Science*, **2007**, 316, 285-8	33.3	124
97	Lymphotoxin alpha beta 2 (membrane lymphotoxin) is critically important for resistance to Leishmania major infection in mice. *Journal of Immunology*, **2007**, 179, 5358-66	5.3	15
96	The role of lymphotoxin receptor signaling in diseases. *Current Molecular Medicine*, **2007**, 7, 567-78	2.5	23
95	Developmental pathway of CD4+CD8- medullary thymocytes during mouse ontogeny and its defect in Aire-/- mice. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 18175-80	11.5	52
94	Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. *Journal of Experimental Medicine*, **2007**, 204, 49-55	16.6	311
93	Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. *Journal of Cell Biology*, **2007**, 176, i6-i6	7.3	
92	Inhibition of Th2-mediated allergic airway inflammatory disease by CD137 costimulation. *Journal of Immunology*, **2006**, 177, 814-21	5.3	23
91	Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. *Journal of Immunology*, **2006**, 177, 739-47	5.3	347
90	Lymphotoxin pathway-directed, autoimmune regulator-independent central tolerance to arthritogenic collagen. *Journal of Immunology*, **2006**, 177, 290-7	5.3	46
89	Recruitment and activation of naive T cells in the islets by lymphotoxin beta receptor-dependent tertiary lymphoid structure. *Immunity*, **2006**, 25, 499-509	32.3	114
88	Coordination between NF-kappaB family members p50 and p52 is essential for mediating LTbetaR signals in the development and organization of secondary lymphoid tissues. *Blood*, **2006**, 107, 1048-55	2.2	84
87	NK-cell activation by LIGHT triggers tumor-specific CD8+ T-cell immunity to reject established tumors. *Blood*, **2006**, 107, 1342-51	2.2	123

86	Tumor-infiltrating T lymphocytes: friends or foes?. *Laboratory Investigation*, **2006**, 86, 231-45	5.9	218
85	The role of stroma in immune recognition and destruction of well-established solid tumors. *Current Opinion in Immunology*, **2006**, 18, 226-31	7.8	103
84	NF-kappaB2 is required for the establishment of central tolerance through an Aire-dependent pathway. *Journal of Clinical Investigation*, **2006**, 116, 2964-71	15.9	107
83	Interaction of mature CD3+CD4+ T cells with dendritic cells triggers the development of tertiary lymphoid structures in the thyroid. *Journal of Clinical Investigation*, **2006**, 116, 2622-32	15.9	76
82	Coordinated epithelial NHE3 inhibition and barrier dysfunction are required for TNF-mediated diarrhea in vivo. *Journal of Clinical Investigation*, **2006**, 116, 2682-94	15.9	160
81	Response to Field. *Journal of Clinical Investigation*, **2006**, 116, 3088-3089	15.9	3
80	Autoimmune Diseases **2006**, 97-115		
79	Recognition of host immune activation by Pseudomonas aeruginosa. *Science*, **2005**, 309, 774-7	33.3	256
78	Tumor necrosis factor family members and inflammatory bowel disease. *Immunological Reviews*, **2005**, 204, 144-55	11.3	62
77	Blockade of lymphotoxin pathway exacerbates autoimmune arthritis by enhancing the Th1 response. *Arthritis and Rheumatism*, **2005**, 52, 3202-9		21
76	The balance of immune responses: costimulation verse coinhibition. *Journal of Molecular Medicine*, **2005**, 83, 193-202	5.5	59
75	Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. *Journal of Experimental Medicine*, **2005**, 201, 779-91	16.6	363
74	Regulation of follicular dendritic cell networks by activated T cells: the role of CD137 signaling. *Journal of Immunology*, **2005**, 175, 884-90	5.3	25
73	Lymphotoxin-beta receptor-dependent genes in lymph node and follicular dendritic cell transcriptomes. *Journal of Immunology*, **2005**, 174, 5526-36	5.3	53
72	Stimulating lymphotoxin beta receptor on the dendritic cells is critical for their homeostasis and expansion. *Journal of Immunology*, **2005**, 175, 6997-7002	5.3	61
71	Contribution of the lymphotoxin beta receptor to liver regeneration. *Journal of Immunology*, **2005**, 175, 1295-300	5.3	58
70	The critical role of LIGHT in promoting intestinal inflammation and Crohn disease. *Journal of Immunology*, **2005**, 174, 8173-82	5.3	72
69	The role of herpesvirus entry mediator as a negative regulator of T cell-mediated responses. *Journal of Clinical Investigation*, **2005**, 115, 711-7	15.9	148

68	Blockade of lymphotoxin signaling inhibits the clinical expression of murine graft-versus-host skin disease. *Journal of Immunology*, **2004**, 172, 1630-6	5.3	16
67	The human BCL6 transgene promotes the development of lymphomas in the mouse. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 14198-203	11.5	68
66	Priming of naive T cells inside tumors leads to eradication of established tumors. *Nature Immunology*, **2004**, 5, 141-9	19.1	294
65	The role of LIGHT in T cell-mediated immunity. *Immunologic Research*, **2004**, 30, 201-14	4.3	27
64	A role for lymphotoxin in the acquisition of Ly49 receptors during NK cell development. *European Journal of Immunology*, **2004**, 34, 2699-707	6.1	24
63	Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection. *Journal of Clinical Investigation*, **2004**, 113, 694-700	15.9	131
62	Dysregulated LIGHT expression on T cells mediates intestinal inflammation and contributes to IgA nephropathy. *Journal of Clinical Investigation*, **2004**, 113, 826-35	15.9	81
61	Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. *Journal of Experimental Medicine*, **2003**, 198, 1023-34	16.6	179
60	Membrane lymphotoxin is required for resistance to Theiler's virus infection. *International Immunology*, **2003**, 15, 955-62	4.9	19
59	Lymphotoxin is required for maintaining physiological levels of serum IgE that minimizes Th1-mediated airway inflammation. *Journal of Experimental Medicine*, **2003**, 198, 1643-52	16.6	40
58	Secondary lymphoid organs are important but not absolutely required for allograft responses. *American Journal of Transplantation*, **2003**, 3, 259-66	8.7	47
57	Tumor immunity meets autoimmunity: antigen levels and dendritic cell maturation. *Current Opinion in Immunology*, **2003**, 15, 725-30	7.8	44
56	Lymphoid microenvironment in the gut for immunoglobulin A and inflammation. *Immunological Reviews*, **2003**, 195, 190-201	11.3	11
55	Positioning of follicular dendritic cells within the spleen controls prion neuroinvasion. *Nature*, **2003**, 425, 957-62	50.4	170
54	Lymphotoxin pathway directs thymic Aire expression. *Nature Immunology*, **2003**, 4, 1121-7	19.1	174
53	Co-stimulation agonists as a new immunotherapy for autoimmune diseases. *Trends in Molecular Medicine*, **2003**, 9, 483-9	11.5	6
52	Complementary role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells. *Journal of Experimental Medicine*, **2003**, 197, 985-95	16.6	67
51	B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. *Journal of Experimental Medicine*, **2003**, 197, 1721-30	16.6	122

50	LIGHT (a cellular ligand for herpes virus entry mediator and lymphotoxin receptor)-mediated thymocyte deletion is dependent on the interaction between TCR and MHC/self-peptide. *Journal of Immunology*, **2003**, 170, 3986-93	5.3	24
49	Differential regulation of CCL21 in lymphoid/nonlymphoid tissues for effectively attracting T cells to peripheral tissues. *Journal of Clinical Investigation*, **2003**, 112, 1495-505	15.9	73
48	The complementation of lymphotoxin deficiency with LIGHT, a newly discovered TNF family member, for the restoration of secondary lymphoid structure and function. *European Journal of Immunology*, **2002**, 32, 1969-79	6.1	65
47	Signaling via LTbetaR on the lamina propria stromal cells of the gut is required for IgA production. *Nature Immunology*, **2002**, 3, 576-82	19.1	134
46	B cells control the migration of a subset of dendritic cells into B cell follicles via CXC chemokine ligand 13 in a lymphotoxin-dependent fashion. *Journal of Immunology*, **2002**, 168, 5117-23	5.3	98
45	Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis. *Journal of Immunology*, **2002**, 168, 1457-65	5.3	164
44	Immunology. Autoreactive B cells migrate into T cell territory. *Science*, **2002**, 297, 2006-8	33.3	5
43	Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. *Nature Medicine*, **2002**, 8, 1405-13	50.5	152
42	Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. *Immunity*, **2002**, 17, 737-47	32.3	199
41	Blockade of LIGHT/LT and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease. *Journal of Clinical Investigation*, **2002**, 109, 549-557	15.9	60
40	Blockade of LIGHT/LTbeta and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease. *Journal of Clinical Investigation*, **2002**, 109, 549-57	15.9	29
39	Confounding factors complicate conclusions in aly model. *Nature Medicine*, **2001**, 7, 1165-6	50.5	13
38	Complementary effects of TNF and lymphotoxin on the formation of germinal center and follicular dendritic cells. *Journal of Immunology*, **2001**, 166, 330-7	5.3	66
37	The critical role of LIGHT, a TNF family member, in T cell development. *Journal of Immunology*, **2001** , 167, 5099-105	5.3	66
36	Signal via lymphotoxin-beta R on bone marrow stromal cells is required for an early checkpoint of NK cell development. *Journal of Immunology*, **2001**, 166, 1684-9	5.3	55
35	Cutting edge: membrane lymphotoxin regulates CD8(+) T cell-mediated intestinal allograft rejection. *Journal of Immunology*, **2001**, 167, 4796-800	5.3	46
34	Reversal of spontaneous autoimmune insulitis in nonobese diabetic mice by soluble lymphotoxin receptor. *Journal of Experimental Medicine*, **2001**, 193, 1327-32	16.6	106
33	Essential role of lymph nodes in contact hypersensitivity revealed in lymphotoxin-alpha-deficient mice. *Journal of Experimental Medicine*, **2001**, 193, 1227-38	16.6	51

32	The regulation of T cell homeostasis and autoimmunity by T cell-derived LIGHT. *Journal of Clinical Investigation*, **2001**, 108, 1771-80	15.9	89
31	The regulation of T cell homeostasis and autoimmunity by T cell-derived LIGHT. *Journal of Clinical Investigation*, **2001**, 108, 1771-1780	15.9	181
30	Antigen persistence is required for somatic mutation and affinity maturation of immunoglobulin. *European Journal of Immunology*, **2000**, 30, 2226-34	6.1	42
29	Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. *Nature Medicine*, **2000**, 6, 283-9	50.5	278
28	Impaired affinity maturation in Cr2-/- mice is rescued by adjuvants without improvement in germinal center development. *Journal of Immunology*, **2000**, 165, 3119-27	5.3	82
27	Lymphotoxin-alpha-dependent spleen microenvironment supports the generation of memory B cells and is required for their subsequent antigen-induced activation. *Journal of Immunology*, **2000**, 164, 2508-14	5.3	57
26	Enhanced growth of primary tumors in cancer-prone mice after immunization against the mutant region of an inherited oncoprotein. *Journal of Experimental Medicine*, **2000**, 191, 1945-56	16.6	51
25	Antigen persistence is required for somatic mutation and affinity maturation of immunoglobulin. *European Journal of Immunology*, **2000**, 30, 2226	6.1	33
24	The requirement of membrane lymphotoxin for the presence of dendritic cells in lymphoid tissues. *Journal of Experimental Medicine*, **1999**, 190, 629-38	16.6	131
23	Requirement for membrane lymphotoxin in natural killer cell development. *Proceedings of the National Academy of Sciences of the United States of America*, **1999**, 96, 6336-40	11.5	112
22	Development and maturation of secondary lymphoid tissues. *Annual Review of Immunology*, **1999**, 17, 399-433	34.7	556
21	Cytokine regulation of secondary lymphoid organ development. *Current Opinion in Immunology*, **1998**, 10, 289-97	7.8	107
20	B lymphocytes induce the formation of follicular dendritic cell clusters in a lymphotoxin alpha-dependent fashion. *Journal of Experimental Medicine*, **1998**, 187, 1009-18	16.6	247
19	Distinct roles of lymphotoxin alpha and the type I tumor necrosis factor (TNF) receptor in the establishment of follicular dendritic cells from non-bone marrow-derived cells. *Journal of Experimental Medicine*, **1997**, 186, 1997-2004	16.6	107
18	Lymphotoxin-alpha (LTalpha) supports development of splenic follicular structure that is required for IgG responses. *Journal of Experimental Medicine*, **1997**, 185, 2111-20	16.6	166
17	Independent signals regulate development of primary and secondary follicle structure in spleen and mesenteric lymph node. *Proceedings of the National Academy of Sciences of the United States of America*, **1997**, 94, 5739-43	11.5	85
16	Lymphotoxin-alpha-deficient and TNF receptor-I-deficient mice define developmental and functional characteristics of germinal centers. *Immunological Reviews*, **1997**, 156, 137-44	11.3	118
15	Multimodality therapy of an acquired factor V inhibitor. *American Journal of Hematology*, **1996**, 51, 315-8	7.1	24

14	Decreased macrophage-mediated cytotoxicity in mammary-tumor-bearing mice is related to alteration of nitric-oxide production and/or release. *International Journal of Cancer*, **1995**, 60, 660-7	7.5	26
13	Regulation of leukocyte binding to endothelial tissues by tumor-derived GM-CSF. *International Journal of Cancer*, **1992**, 50, 585-8	7.5	26
12	Modulation of the immune system by mammary tumor-derived factors. *Cancer Investigation*, **1991**, 9, 643-53	2.1	34
11	Splenic macrophages from tumor-bearing mice co-expressing MAC-1 and MAC-2 antigens exert immunoregulatory functions via two distinct mechanisms. *Journal of Leukocyte Biology*, **1991**, 49, 126-38	6.5	51
10	Food-induced asthma in China: an analysis in 40 cases. *Journal of Asthma*, **1991**, 28, 415-8	1.9	3
9	The role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma. I. Induction of regulatory macrophages in normal mice by the in vivo administration of rGM-CSF. *Journal of Immunology*, **1991**, 146, 783-9	5.3	51
8	Role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma. II. Down-regulation of macrophage-mediated cytotoxicity by tumor-derived granulocyte-macrophage colony-stimulating factor. *Journal of Immunology*, **1991**, 147, 2816-23	5.3	54
7	Expansion of immunoregulatory macrophages by granulocyte-macrophage colony-stimulating factor derived from a murine mammary tumor. *Cancer Research*, **1990**, 50, 227-34	10.1	93
6	Thymic atrophy induced by murine mammary adenocarcinoma in vivo. *In Vivo*, **1989**, 3, 1-5	2.3	9
5	Immunogenicity and safety of the homogenous booster shot of a recombinant fusion protein vaccine (V-01) against COVID-19 in healthy adult participants primed with a two-dose regimen		1
4	Immune Mechanisms Orchestrate Tertiary Lymphoid Structures in Tumors Via Cancer-Associated Fibroblasts. *SSRN Electronic Journal*,	1	4
3	Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease		45
2	Tissue-resident CD4+ T helper cells assist protective respiratory mucosal B and CD8+ T cell memory responses		3
1	The landscape of antigen-specific T cells in human cancers		2